Joint Surgery Department, The Second People's Hospital of Zhangye City, Zhangye, China.
Department of Spine Surgery, The Third Affiliated Hospital, 144991Sun Yat-sen University, Guangzhou, China.
Cancer Control. 2022 Jan-Dec;29:10732748221076683. doi: 10.1177/10732748221076683.
Currently, although the improvement of surgical techniques and the development of chemotherapy drugs have brought a certain degree of development to the treatment of osteosarcoma, the treatment of osteosarcoma has many shortcomings, and its treatment is limited. MiRNAs and exosomes can be used as diagnostic tools, and they play an important role in the occurrence and chemotherapy resistance of osteosarcoma. Therefore, providing a new method for the treatment of osteosarcoma is the key to solving this problem. To systematically summarize the research status of exoskeleton drug-loaded miRNA in osteosarcoma, we identified and evaluated 208 studies and found that exosome-carrying miRNA can be used as an index for the diagnosis and prognosis of osteosarcoma and share a certain relationship with chemosensitivity. In addition, exosomes can also be used as a carrier of genetic drugs able to regulate the progression of osteosarcoma. Based on the above findings, we propose suggestions for the future development of this field, aiming to bring new ideas for the early diagnosis and treatment of osteosarcoma.
目前，尽管手术技术的提高和化疗药物的发展给骨肉瘤的治疗带来了一定程度的发展，但骨肉瘤的治疗仍存在许多缺陷，其治疗受到限制。miRNAs 和外泌体可用作诊断工具，它们在骨肉瘤的发生和化疗耐药性中发挥重要作用。因此，为骨肉瘤的治疗提供新方法是解决这一问题的关键。为了系统地总结外泌体载 miRNA 药物在骨肉瘤中的研究现状，我们鉴定和评估了 208 项研究，发现外泌体携带的 miRNA 可作为骨肉瘤诊断和预后的指标，与化疗敏感性有一定的关系。此外，外泌体还可以作为遗传药物的载体，调节骨肉瘤的进展。基于上述发现，我们对该领域的未来发展提出了建议，旨在为骨肉瘤的早期诊断和治疗带来新的思路。
